Confronti finanziari Arbutus Biopharma Corporation

Azioni

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 12/12/2025			Variaz. 5gg	Var. 1 gen.
4,710 ^USD	+0,86%		+6,56%	+44,04%

05/12	Trevi Therapeutics, Inc. nomina David Hastings come nuovo Chief Financial Officer a partire dal 6 gennaio 2026	CI
04/12	Trevi Therapeutics nomina David Hastings come direttore finanziario	MT

Settore:

Regione:

Asse X:

Principali concorrenti

Aggiungi a un elenco 0 selezionato Solo clienti o iscritti possono usare questa funzione Accedi Registrati	Fatturato (Y-1)	Margine netto (Y-1)	Margine EBIT (Y-1)	ROE (Y-1)	ROA (Y-1)	Leverage (Y-1)
ARBUTUS BIOPHARMA CORPORATION	6,12 Mln	-1.133,04%	-1.236,74%	-	-	-
LONZA GROUP AG	7,25 Mrd	9,67%	17,9%	6,77%	3,48%	1.5x
IQVIA HOLDINGS INC.	15,4 Mrd	8,91%	20,12%	33,53%	5,12%	3.33x
BEONE MEDICINES AG	3,81 Mrd	-16,92%	-14,91%	-17,71%	-11,1%	4.46x
CELLTRION, INC.	2,41 Mrd	11,88%	13,83%	2,46%	2,14%	1.28x
MEDPACE HOLDINGS, INC.	2,11 Mrd	19,17%	21,38%	58,42%	21,52%	-1.39x
ICON PUBLIC LIMITED COMPANY	8,28 Mrd	9,56%	19,29%	12,39%	6,87%	1.66x
ASCENDIS PHARMA A/S	376 Mln	-103,97%	-76,66%	-	-37,71%	-1.14x
IONIS PHARMACEUTICALS, INC.	705 Mln	-64,4%	-67,38%	-93,12%	-15,15%	2.26x
TEMPUS AI, INC.	693 Mln	-107,63%	-20,47%	-	-25,37%	0.13x
EUROFINS SCIENTIFIC SE	7,2 Mrd	5,84%	14,63%	7,8%	3,73%	1.93x
QIAGEN N.V.	1,98 Mrd	4,23%	28,66%	13,31%	8,32%	0.34x
ABIVAX	12,94 Mln	-1.409,6%	-1.383,2%	-148,95%	-	0.4x
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	4,05 Mrd	0,25%	19,9%	15,1%	6,78%	2.05x
BIO-TECHNE CORPORATION	1,22 Mrd	6,02%	31,45%	15,37%	11,65%	0.43x
BLUEPRINT MEDICINES CORPORATION	509 Mln	-13,19%	-41,67%	-31,26%	-21,6%	-0.14x
KYMERA THERAPEUTICS, INC.	47,07 Mln	-475,57%	-555,82%	-36,38%	-28,81%	3.35x
PHARMARON BEIJING CO., LTD.	1,68 Mrd	14,61%	17,14%	13,7%	7,12%	1.33x
Media	3,21 Mrd	-179,68%	-177,36%	-9,9%	-3,94%	1,28x
Media ponderata per Capi.	5,05 Mrd	-70,8%	-61,64%	-1,73%	-2,19%	1,70x